Last week, a team from Synpromics was in Washington D.C. for the 22nd annual ASGCT meeting. A busy and successful few days for the team, they presented three posters, participated in a Tools & Technology Forum, hosted two Industry Technology Breakfast Meetings for sector leaders, and conducted over 30 one-on-one business development meetings. It was a highly valuable week for the Synpromics team and confirmed that the sector shows substantial growth and a broad need for gene regulation technology to support second and third generation gene medicine products.
CSO Michael Roberts presented to a packed room as part of the Tools & Technologies Forum

On the first day, CSO Michael Roberts presented to a packed room as part of the Tools & Technologies Forum. It was standing room only during his presentation: Mastering Gene Control to Enable the Next Generation of Gene Medicines.

On days two and three, Synpromics held two technology featured breakfast meetings for invited industry leaders prior to the start of ASGCT general sessions. These forums were extremely well attended, with representatives from over 20 different companies attending on both days. With a Synpromics technology presentation and subsequent interactive discussion, it was an opportunity for expert dialogue about the applications and benefits of the novel Synpromics promoter platforms. On Tuesday morning, Dr Graham Whyteside presented on the topic of Liver Directed Inducible Control of Gene Therapies and discussed Synpromics’ small molecule responsive system for tight gene control in the liver. On Wednesday morning, Dr Jo Ng from University College London, presented on the topic of Development of Novel CNS Cell Type Selective Promoters for the Treatment of Juvenile Parkinson’s Disease.

Dr Jo Ng presenting at the breakfast meeting on day three

Synpromics and collaborators presented three posters throughout the conference. There was a constant stream of interest in Synpromics synthetic promoter development and PromPT® technology at these sessions. Attendees were able to engage in discussion with not only Synpromics scientists but also key industry and academic partners, who have incorporated Synpromics’ synthetic promoters into their novel gene therapy products.

Three posters were presented at the conference:

Dr Graham Whyteside presents his poster

Dr Graham Whyteside presents his poster

On Thursday, uniQure gave two oral presentations. View the first presentation, entitled Towards AAV5-mediated Gene Therapy for Hemophilia A with a Factor IX Variant that functions independently of FVIII. View the presentation on the topic of Development of an AAV5-based Gene Therapy for Fabry Disease.

Overall, the annual ASGCT conference continues to be a highly valuable venue and resource for Synpromics. The chance to showcase our novel technology platforms and provide scientific updates, the opportunity to meet with prospective partners in 1:1 business development meetings, and the ability to robustly engage with our current partners in our ongoing collaborations is paramount. ASGCT 2019 demonstrated that there is continued, fast-paced innovation in cell and gene therapy. The Synpromics promoter and gene control technology will play an integral part in cell and gene medicine products across multiple therapeutic areas. Please get in touch if you missed us or if you want to find out more.